IN2014DN11112A - - Google Patents

Download PDF

Info

Publication number
IN2014DN11112A
IN2014DN11112A IN11112DEN2014A IN2014DN11112A IN 2014DN11112 A IN2014DN11112 A IN 2014DN11112A IN 11112DEN2014 A IN11112DEN2014 A IN 11112DEN2014A IN 2014DN11112 A IN2014DN11112 A IN 2014DN11112A
Authority
IN
India
Prior art keywords
formula
alzheimer
definitions
disease
prevention
Prior art date
Application number
Other languages
English (en)
Inventor
Hua Bai
Xuyang Zhao
Jinqing Zhong
Yongxiang Gong
Qifeng Zhu
Xiaoyu Liu
Xiaohe Zheng
Lifei Liu
Original Assignee
Zhejiang Hisun Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN11112(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhejiang Hisun Pharm Co Ltd filed Critical Zhejiang Hisun Pharm Co Ltd
Publication of IN2014DN11112A publication Critical patent/IN2014DN11112A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN11112DEN2014 2012-07-03 2013-07-03 IN2014DN11112A (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210226125.7A CN103524515B (zh) 2012-07-03 2012-07-03 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
PCT/CN2013/000813 WO2014005421A1 (zh) 2012-07-03 2013-07-03 苯并间二氧杂环戊烯衍生物及其制备方法和用途

Publications (1)

Publication Number Publication Date
IN2014DN11112A true IN2014DN11112A (tr) 2015-09-25

Family

ID=49881293

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11112DEN2014 IN2014DN11112A (tr) 2012-07-03 2013-07-03

Country Status (26)

Country Link
US (1) US9346818B2 (tr)
EP (1) EP2871184B1 (tr)
JP (1) JP6113275B2 (tr)
KR (1) KR101650776B1 (tr)
CN (2) CN103524515B (tr)
AU (1) AU2013286523B2 (tr)
BR (1) BR112014032964A2 (tr)
CA (1) CA2878000C (tr)
CL (1) CL2014003607A1 (tr)
DK (1) DK2871184T3 (tr)
EA (1) EA026210B1 (tr)
ES (1) ES2645643T3 (tr)
HK (1) HK1202857A1 (tr)
IL (1) IL236395A (tr)
IN (1) IN2014DN11112A (tr)
MX (1) MX357774B (tr)
MY (1) MY167075A (tr)
NO (1) NO2871184T3 (tr)
NZ (1) NZ703549A (tr)
PE (1) PE20150349A1 (tr)
PH (1) PH12015500012B1 (tr)
PT (1) PT2871184T (tr)
SG (1) SG11201500007WA (tr)
UA (1) UA113444C2 (tr)
WO (1) WO2014005421A1 (tr)
ZA (1) ZA201500692B (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
CN105859732B (zh) * 2016-04-11 2018-04-06 浙江海正药业股份有限公司 制备ad‑35的工艺
KR20190008225A (ko) * 2016-05-13 2019-01-23 델노바 인코퍼레이티드 화학적 신경차단으로 인한 부작용의 치료
CN110812358B (zh) * 2018-08-10 2022-04-05 浙江海正药业股份有限公司 化合物ad-35在治疗与胃肠蠕动障碍相关疾病中的应用
CN113185447B (zh) * 2021-05-06 2023-07-21 四川大学 邻苯二甲酰半胱酰胺类化合物、其制备方法和用途
WO2023116915A1 (zh) * 2021-12-24 2023-06-29 珠海市藤栢医药有限公司 AChE/SERT双靶点抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087541A (en) * 1975-03-06 1978-05-02 Boehringer Ingelheim Gmbh 2-(Aralkylaminoalkyl)phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPH0610496B2 (ja) * 1987-09-17 1994-02-09 ダイハツ工業株式会社 車両用自動変速機のクラッチ構造
JP2777159B2 (ja) * 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
CA2401711C (en) * 2000-02-29 2008-06-03 Mitsubishi Pharma Corporation Cyclic amide derivatives
WO2003061658A1 (fr) 2002-01-22 2003-07-31 Eisai Co., Ltd. Agent liant de récepteur sigma contenant un dérivé d'indanone
WO2005003092A1 (en) 2003-07-01 2005-01-13 Hetero Drugs Limited Preparation of intermediates for acetyl cholinesterase inhibitors
WO2005076749A2 (en) 2004-02-11 2005-08-25 Jubilant Organosys Limited A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
WO2007077443A1 (en) 2006-01-04 2007-07-12 Cipla Limited Process and intermediate for preparation of donepezil
ES2339816T3 (es) 2006-01-18 2010-05-25 Siena Biotech S.P.A. Moduladores de receptores nicotinicos alfa 7 de acetilcolina y usos terapeuticos de los mismos.
US8247563B2 (en) * 2006-12-11 2012-08-21 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EA026210B1 (ru) 2017-03-31
KR101650776B1 (ko) 2016-08-25
CN103524515B (zh) 2016-07-06
CN103524515A (zh) 2014-01-22
EP2871184A1 (en) 2015-05-13
PH12015500012A1 (en) 2015-03-02
HK1202857A1 (en) 2015-10-09
PT2871184T (pt) 2017-11-14
US9346818B2 (en) 2016-05-24
AU2013286523B2 (en) 2017-06-22
US20150191480A1 (en) 2015-07-09
CL2014003607A1 (es) 2015-03-13
NZ703549A (en) 2015-11-27
EA201590074A1 (ru) 2015-07-30
EP2871184A4 (en) 2015-12-23
PH12015500012B1 (en) 2015-03-02
DK2871184T3 (da) 2017-11-13
CN104395303A (zh) 2015-03-04
EP2871184B1 (en) 2017-09-06
ZA201500692B (en) 2016-01-27
JP2015525740A (ja) 2015-09-07
MX2015000334A (es) 2015-04-14
MY167075A (en) 2018-08-10
SG11201500007WA (en) 2015-02-27
CA2878000C (en) 2020-05-05
KR20150034224A (ko) 2015-04-02
IL236395A (en) 2017-01-31
UA113444C2 (xx) 2017-01-25
BR112014032964A2 (pt) 2017-06-27
IL236395A0 (en) 2015-02-26
CN104395303B (zh) 2017-12-12
AU2013286523A1 (en) 2015-02-05
ES2645643T3 (es) 2017-12-07
MX357774B (es) 2018-07-24
CA2878000A1 (en) 2014-01-09
PE20150349A1 (es) 2015-02-28
WO2014005421A1 (zh) 2014-01-09
JP6113275B2 (ja) 2017-04-12
NO2871184T3 (tr) 2018-02-03

Similar Documents

Publication Publication Date Title
PH12016501750A1 (en) Human plasma kallikrein inhibitors
ZA201701299B (en) Glycosidase inhibitors
IN2015DN01156A (tr)
NZ703064A (en) Inhibitors of hepatitis c virus
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014DN03206A (tr)
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
NZ704863A (en) Bicyclic pyridinones useful as gamma secretase modulators
IN2014KN00948A (tr)
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12015501088A1 (en) Dimeric compounds
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12015500399A1 (en) Azaindolines
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
PH12015500185A1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
MY187891A (en) Tetrahydropyridine derivatives as fabi inhibitors
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders